Source: Basic & Clinical Pharmacology & Toxicology. Unidade: FMRP
Subjects: COVID-19, METALOPROTEINASES, ÍNDICE DE GRAVIDADE DA DOENÇA
ABNT
CAVALCANTE, Gisele Lopes et al. Matrix metalloproteinases are associated with severity of disease among COVID‐19 patients: a possible pharmacological target. Basic & Clinical Pharmacology & Toxicology, v. 134, p. 727-736, 2024Tradução . . Disponível em: https://doi.org/10.1111/bcpt.14001. Acesso em: 16 nov. 2024.APA
Cavalcante, G. L., Bonifácio, L. P., Sanches‐lopes, J. M., Puga, F. G., Carvalho, F. S. de, Bellissimo-Rodrigues, F., & Tanus-Santos, J. E. (2024). Matrix metalloproteinases are associated with severity of disease among COVID‐19 patients: a possible pharmacological target. Basic & Clinical Pharmacology & Toxicology, 134, 727-736. doi:10.1111/bcpt.14001NLM
Cavalcante GL, Bonifácio LP, Sanches‐lopes JM, Puga FG, Carvalho FS de, Bellissimo-Rodrigues F, Tanus-Santos JE. Matrix metalloproteinases are associated with severity of disease among COVID‐19 patients: a possible pharmacological target [Internet]. Basic & Clinical Pharmacology & Toxicology. 2024 ; 134 727-736.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/bcpt.14001Vancouver
Cavalcante GL, Bonifácio LP, Sanches‐lopes JM, Puga FG, Carvalho FS de, Bellissimo-Rodrigues F, Tanus-Santos JE. Matrix metalloproteinases are associated with severity of disease among COVID‐19 patients: a possible pharmacological target [Internet]. Basic & Clinical Pharmacology & Toxicology. 2024 ; 134 727-736.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/bcpt.14001